Table 1 Baseline characteristics of the patients

Age (yrs)

49.0 ± 18.1

Women

29 (78.4)

Time from the onset to study enrolment (weeks)

14.2 ± 18.3

Functional class II/III/IV

4/21/12 (10.8/56.8/32.4)

Idiopathic PAH/connective tissue disorder-associated PAH

18/19 (48.6/51.4)

Death

15 (40.5)

Treatment failure*

20 (54.1)

Use of PAH-specific drug at baseline

   Epoprostenol alone

11 (29.7)

   Sildenafil alone

4 (10.8)

   Bosentan alone

6 (16.2)

   Beraprost alone

13 (35.1)

   Epoprostenol + Sildenafil

1 (2.7)

   Sildenafil + Beraprost

1 (2.7)

   Sildenafil + Bosentan + Beraprost

1 (2.7)

   Oxygen

33 (89.2)